Gene profiling analysis of ALVAC infected human monocyte derived dendritic cells

Vaccine

Volumn 26, Issue 39, 2008, Pages 5004-5013

  Harenberg, Anke ^a   Guillaume, Florine ^a   Ryan, Elizabeth J ^b   Burdin, Nicolas ^a   Spada, Franca ^a  

^a SANOFI PASTEUR   (France)

^b TRINITY COLLEGE DUBLIN   (Ireland)

Author keywords

ALVAC; Dendritic cell; Innate immunity; IRF; Microarray

Indexed keywords

CD40 ANTIGEN; GAMMA INTERFERON INDUCIBLE PROTEIN 10; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERFERON REGULATORY FACTOR 3; INTERFERON REGULATORY FACTOR 7; STAT1 PROTEIN; VIRUS VECTOR;

ARTICLE; CANARYPOX VIRUS; CELL MATURATION; CONTROLLED STUDY; DENDRITIC CELL; FLUORESCENCE ACTIVATED CELL SORTING; GENE EXPRESSION PROFILING; HUMAN; HUMAN CELL; MONOCYTE; NORMAL HUMAN; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; VIRUS CELL INTERACTION; VIRUS RECOMBINANT;

CANARYPOX VIRUS; CHEMOKINE CXCL10; CYTOKINES; DENDRITIC CELLS; GENE EXPRESSION; GENE EXPRESSION PROFILING; HIV ENVELOPE PROTEIN GP120; HIV ENVELOPE PROTEIN GP41; HIV INFECTIONS; HIV-1; HUMANS; IMMUNOBLOTTING; INTERFERON TYPE I; MONOCYTES; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA; UBIQUITINS; VIRAL VACCINES;

EID: 50549101923     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2008.07.050     Document Type: Article

References (57)

1. Marovich M.A. ALVAC-HIV vaccines: clinical trial experience focusing on progress in vaccine development. Expert Rev Vaccines 3 4 Suppl. (2004) S99-S104
2. de Bruyn G., Rossini A.J., Chiu Y.L., Holman D., Elizaga M.L., Frey S.E., et al. Safety profile of recombinant canarypox HIV vaccines. Vaccine 22 5-6 (2004) 704-713
3. Van der Burg S.H., Menon A.G., Redeker A., Bonnet M.C., Drijfhout J.W., Tollenaar R.A., et al. Induction of p53-specific immune responses in colorectal cancer patients receiving a recombinant ALVAC-p53 candidate vaccine. Clin Cancer Res 8 5 (2002) 1019-1027
4. van Baren N., Bonnet M.C., Dreno B., Khammari A., Dorval T., Piperno-Neumann S., et al. Tumoral and immunologic response after vaccination of melanoma patients with an ALVAC virus encoding MAGE antigens recognized by T cells. J Clin Oncol 23 35 (2005) 9008-9021
5. Tartaglia J., Bonnet M.C., Berinstein N., Barber B., Klein M., and Moingeon P. Therapeutic vaccines against melanoma and colorectal cancer. Vaccine 19 17-19 (2001) 2571-2575
6. Belshe R.B., Gorse G.J., Mulligan M.J., Evans T.G., Keefer M.C., Excler J.L., et al. Induction of immune responses to HIV-1 by canarypox virus (ALVAC) HIV-1 and gp120 SF-2 recombinant vaccines in uninfected volunteers. NIAID AIDS Vaccine Evaluation Group. AIDS 12 18 (1998) 2407-2415
7. Clements-Mann M.L., Weinhold K., Matthews T.J., Graham B.S., Gorse G.J., Keefer M.C., et al. Immune responses to human immunodeficiency virus (HIV) type 1 induced by canarypox expressing HIV-1MN gp120, HIV-1SF2 recombinant gp120, or both vaccines in seronegative adults. NIAID AIDS Vaccine Evaluation Group. J Infect Dis 177 5 (1998) 1230-1246
8. Fries L.F., Tartaglia J., Taylor J., Kauffman E.K., Meignier B., Paoletti E., et al. Human safety and immunogenicity of a canarypox-rabies glycoprotein recombinant vaccine: an alternative poxvirus vector system. Vaccine 14 5 (1996) 428-434
9. Salmon-Ceron D., Excler J.L., Sicard D., Blanche P., Finkielstzjen L., Gluckman J.C., et al. Safety and immunogenicity of a recombinant HIV type 1 glycoprotein 160 boosted by a V3 synthetic peptide in HIV-negative volunteers. AIDS Res Hum Retroviruses 11 12 (1995) 1479-1486
10. Gupta K., Hudgens M., Corey L., McElrath M.J., Weinhold K., Montefiori D.C., et al. Safety and immunogenicity of a high-titered canarypox vaccine in combination with rgp120 in a diverse population of HIV-1-uninfected adults: AIDS Vaccine Evaluation Group Protocol 022A. J Acquir Immune Defic Syndr 29 3 (2002) 254-261
11. Egan M.A., Pavlat W.A., Tartaglia J., Paoletti E., Weinhold K.J., Clements M.L., et al. Induction of human immunodeficiency virus type 1 (HIV-1)-specific cytolytic T lymphocyte responses in seronegative adults by a nonreplicating, host-range-restricted canarypox vector (ALVAC) carrying the HIV-1MN env gene. J Infect Dis 171 6 (1995) 1623-1627
12. Konishi E., Kurane I., Mason P.W., Shope R.E., Kanesa-thasan N., Smucny J.J., et al. Induction of Japanese encephalitis virus-specific cytotoxic T lymphocytes in humans by poxvirus-based JE vaccine candidates. Vaccine 16 8 (1998) 842-849
13. Fischer L., Le Gros F.X., Mason P.W., and Paoletti E. A recombinant canarypox virus protects rabbits against a lethal rabbit hemorrhagic disease virus (RHDV) challenge. Vaccine 15 1 (1997) 90-96
14. Boudet F., Chevalier M., Jourdier T.M., Tartaglia J., and Moste C. Modulation of the antibody response to the HIV envelope subunit by co-administration of infectious or heat-inactivated canarypoxvirus (ALVAC) preparations. Vaccine 19 30 (2001) 4267-4275
15. Ryan E.J., Harenberg A., and Burdin N. The Canarypox-virus vaccine vector ALVAC triggers the release of IFN-gamma by Natural Killer (NK) cells enhancing Th1 polarization. Vaccine 25 17 (2007) 3380-3390
16. Taylor J., Meignier B., Tartaglia J., Languet B., VanderHoeven J., Franchini G., et al. Biological and immunogenic properties of a canarypox-rabies recombinant, ALVAC-RG (vCP65) in non-avian species. Vaccine 13 6 (1995) 539-549
17. Ignatius R., Marovich M., Mehlhop E., Villamide L., Mahnke K., Cox W.I., et al. Canarypox virus-induced maturation of dendritic cells is mediated by apoptotic cell death and tumor necrosis factor alpha secretion. J Virol 74 23 (2000) 11329-11338
18. Motta I., Andre F., Lim A., Tartaglia J., Cox W.I., Zitvogel L., et al. Cross-presentation by dendritic cells of tumor antigen expressed in apoptotic recombinant canarypox virus-infected dendritic cells. J Immunol 167 3 (2001) 1795-1802
19. Engelmayer J., Larsson M., Lee A., Lee M., Cox W.I., Steinman R.M., et al. Mature dendritic cells infected with canarypox virus elicit strong anti-human immunodeficiency virus CD8+ and CD4+ T-cell responses from chronically infected individuals. J Virol 75 5 (2001) 2142-2153
20. Berencsi K., Gyulai Z., Gonczol E., Pincus S., Cox W.I., Michelson S., et al. A canarypox vector-expressing cytomegalovirus (CMV) phosphoprotein 65 induces long-lasting cytotoxic T cell responses in human CMV-seronegative subjects. J Infect Dis 183 8 (2001) 1171-1179
21. Klein M. Current progress in the development of human immunodeficiency virus vaccines: research and clinical trials. Vaccine 19 17-19 (2001) 2210-2215
22. Dolin R. HIV vaccines for prevention of infection and disease in humans. Infect Dis Clin North Am 14 4 (2000) 1001-1016
23. Goepfert P.A., Horton H., McElrath M.J., Gurunathan S., Ferrari G., Tomaras G.D., et al. High-dose recombinant Canarypox vaccine expressing HIV-1 protein, in seronegative human subjects. J Infect Dis 192 7 (2005) 1249-1259
24. Bos R., van Duikeren S., van Hall T., Lauwen M.M., Parrington M., Berinstein N.L., et al. Characterization of antigen-specific immune responses induced by canarypox virus vaccines. J Immunol 179 9 (2007) 6115-6122
25. Lenschow D.J., Giannakopoulos N.V., Gunn L.J., Johnston C., O'Guin A.K., Schmidt R.E., et al. Identification of interferon-stimulated gene 15 as an antiviral molecule during Sindbis virus infection in vivo. J Virol 79 22 (2005) 13974-13983
26. Lenschow D.J., Lai C., Frias-Staheli N., Giannakopoulos N.V., Lutz A., Wolff T., et al. IFN-stimulated gene 15 functions as a critical antiviral molecule against influenza, herpes, and Sindbis viruses. Proc Natl Acad Sci USA 104 4 (2007) 1371-1376
27. D'Cunha J., Ramanujam S., Wagner R.J., Witt P.L., Knight Jr. E., and Borden E.C. In vitro and in vivo secretion of human ISG15, an IFN-induced immunomodulatory cytokine. J Immunol 157 9 (1996) 4100-4108
28. D'Cunha J., Knight Jr. E., Haas A.L., Truitt R.L., and Borden E.C. Immunoregulatory properties of ISG15, an interferon-induced cytokine. Proc Natl Acad Sci USA 93 1 (1996) 211-215
29. Knight Jr. E., and Cordova B. IFN-induced 15-kDa protein is released from human lymphocytes and monocytes. J Immunol 146 7 (1991) 2280-2284
30. Takaoka A., Wang Z., Choi M.K., Yanai H., Negishi H., Ban T., et al. DAI (DLM-1/ZBP1) is a cytosolic DNA sensor and an activator of innate immune response. Nature 448 7152 (2007) 501-505
31. Honda K., and Taniguchi T. IRFs: master regulators of signalling by Toll-like receptors and cytosolic pattern-recognition receptors. Nat Rev Immunol 6 9 (2006) 644-658
32. Yu Q., Jones B., Hu N., Chang H., Ahmad S., Liu J., et al. Comparative analysis of tropism between canarypox (ALVAC) and vaccinia viruses reveals a more restricted and preferential tropism of ALVAC for human cells of the monocytic lineage. Vaccine 24 40-41 (2006) 6376-6391
33. Velten F.W., Rambow F., Metharom P., and Goerdt S. Enhanced T-cell activation and T-cell-dependent IL-2 production by CD83+, CD25high, CD43high human monocyte-derived dendritic cells. Mol Immunol 44 7 (2007) 1544-1550
34. Guerra S., Najera J.L., Gonzalez J.M., Lopez-Fernandez L.A., Climent N., Gatell J.M., et al. Distinct gene expression profiling after infection of immature human monocyte-derived dendritic cells by the attenuated poxvirus vectors MVA and NYVAC. J Virol 81 16 (2007) 8707-8721
35. Asselin-Paturel C., and Trinchieri G. Production of type I interferons: plasmacytoid dendritic cells and beyond. J Exp Med 202 4 (2005) 461-465
36. Nakaya T., Sato M., Hata N., Asagiri M., Suemori H., Noguchi S., et al. Gene induction pathways mediated by distinct IRFs during viral infection. Biochem Biophys Res Commun 283 5 (2001) 1150-1156
37. Wong J.J., Pung Y.F., Sze N.S., and Chin K.C. HERC5 is an IFN-induced HECT-type E3 protein ligase that mediates type I IFN-induced ISGylation of protein targets. Proc Natl Acad Sci USA 103 28 (2006) 10735-10740
38. Dastur A., Beaudenon S., Kelley M., Krug R.M., and Huibregtse J.M. Herc5, an interferon-induced HECT E3 enzyme, is required for conjugation of ISG15 in human cells. J Biol Chem 281 7 (2006) 4334-4338
39. Yuan W., and Krug R.M. Influenza B virus NS1 protein inhibits conjugation of the interferon (IFN)-induced ubiquitin-like ISG15 protein. EMBO J 20 3 (2001) 362-371
40. Zhao C., Denison C., Huibregtse J.M., Gygi S., and Krug R.M. Human ISG15 conjugation targets both IFN-induced and constitutively expressed proteins functioning in diverse cellular pathways. Proc Natl Acad Sci USA 102 29 (2005) 10200-10205
41. Hutchings C.L., Gilbert S.C., Hill A.V., and Moore A.C. Novel protein and poxvirus-based vaccine combinations for simultaneous induction of humoral and cell-mediated immunity. J Immunol 175 1 (2005) 599-606
42. Poulet H., Minke J., Pardo M.C., Juillard V., Nordgren B., and Audonnet J.C. Development and registration of recombinant veterinary vaccines. The example of the canarypox vector platform. Vaccine 25 30 (2007) 5606-5612
43. Akira S., Uematsu S., and Takeuchi O. Pathogen recognition and innate immunity. Cell 124 4 (2006) 783-801
44. Zhu J., Martinez J., Huang X., and Yang Y. Innate immunity against vaccinia virus is mediated by TLR2 and requires TLR-independent production of IFN-beta. Blood 109 2 (2007) 619-625
45. Banchereau J., and Steinman R.M. Dendritic cells and the control of immunity. Nature 392 6673 (1998) 245-252
46. Liu M.T., Keirstead H.S., and Lane T.E. Neutralization of the chemokine CXCL10 reduces inflammatory cell invasion and demyelination and improves neurological function in a viral model of multiple sclerosis. J Immunol 167 7 (2001) 4091-4097
47. Trifilo M.J., Montalto-Morrison C., Stiles L.N., Hurst K.R., Hardison J.L., Manning J.E., et al. CXC chemokine ligand 10 controls viral infection in the central nervous system: evidence for a role in innate immune response through recruitment and activation of natural killer cells. J Virol 78 2 (2004) 585-594
48. Walsh K.B., Edwards R.A., Romero K.M., Kotlajich M.V., Stohlman S.A., and Lane T.E. Expression of CXC chemokine ligand 10 from the mouse hepatitis virus genome results in protection from viral-induced neurological and liver disease. J Immunol 179 2 (2007) 1155-1165
49. Liu M.T., Chen B.P., Oertel P., Buchmeier M.J., Armstrong D., Hamilton T.A., et al. The T cell chemoattractant IFN-inducible protein 10 is essential in host defense against viral-induced neurologic disease. J Immunol 165 5 (2000) 2327-2330
50. Dufour J.H., Dziejman M., Liu M.T., Leung J.H., Lane T.E., and Luster A.D. IFN-gamma-inducible protein 10 (IP-10; CXCL10)-deficient mice reveal a role for IP-10 in effector T cell generation and trafficking. J Immunol 168 7 (2002) 3195-3204
51. Megjugorac N.J., Young H.A., Amrute S.B., Olshalsky S.L., and Fitzgerald-Bocarsly P. Virally stimulated plasmacytoid dendritic cells produce chemokines and induce migration of T and NK cells. J Leukoc Biol 75 3 (2004) 504-514
52. Pitha-Rowe I.F., and Pitha P.M. Viral defense, carcinogenesis and ISG15: novel roles for an old ISG. Cytokine Growth Factor Rev 18 5-6 (2007) 409-417
53. Giannakopoulos N.V., Luo J.K., Papov V., Zou W., Lenschow D.J., Jacobs B.S., et al. Proteomic identification of proteins conjugated to ISG15 in mouse and human cells. Biochem Biophys Res Commun 336 2 (2005) 496-506
54. O'Neill L.A., and Bowie A.G. The family of five: TIR-domain-containing adaptors in Toll-like receptor signalling. Nat Rev Immunol 7 5 (2007) 353-364
55. Marovich M.A., Mascola J.R., Eller M.A., Louder M.K., Caudrelier P.A., El Habib R., et al. Preparation of clinical-grade recombinant canarypox-human immunodeficiency virus vaccine-loaded human dendritic cells. J Infect Dis 186 9 (2002) 1242-1252
56. Nociari M., Ocheretina O., Schoggins J.W., and Falck-Pedersen E. Sensing infection by adenovirus: toll-like receptor-independent viral DNA recognition signals activation of the interferon regulatory factor 3 master regulator. J Virol 81 8 (2007) 4145-4157
57. Waibler Z., Anzaghe M., Ludwig H., Akira S., Weiss S., Sutter G., et al. Modified vaccinia virus Ankara induces toll-like receptor-independent type I interferon responses. J Virol 81 22 (2007) 12102-12110